Top Markets
#1 ONFA ONFA +225.03%
#2 Resolv wstUSR Resolv wstUSR +198.11%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 NKN NKN +36.62%
#6 DeAgentAI DeAgentAI +32.88%
#7 StakeStone StakeStone +27.06%
#8 BLOCKv BLOCKv +26.09%
#9 KONET KONET +22.11%
#10 OpenVPP OpenVPP +21.99%
Coin of the day
ONFA ONFA
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Kedudukan dalam Saham #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Harga Saham
$0.5275
Modal Pasaran
$1.25M
Perubahan (1 hari)
-3.56%
Perubahan (1 tahun)
-83.77%
Negara
US
Perdagangan Ensysce Biosciences, Inc. (ENSC)

Kategori

Healthcare
Pendapatan untuk Ensysce Biosciences, Inc. (ENSC)
Pendapatan pada Sep 2025 TTM: $-10.97M
Menurut laporan kewangan terkini Ensysce Biosciences, Inc., pendapatan semasa syarikat ialah $-10.97M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-10.63M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-24.21M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Ensysce Biosciences, Inc. dari 2017 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-10.97M 37.39%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -186,530.54%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -42,414.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -47,768.53%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,581.29%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -14,811.33%
AU